PEMBROLIZUMAB
pembrolizumab 100 mg/4 mL injection, 4 mL vial
PEMBROLIZUMAB (15210M)
15210M
Manner of administration:Injection
Restriction 17992
Indication: Intermediate or high risk of recurrence clear cell variant renal cell carcinoma (RCC)
Quantities & Cost
| Max amount | # of repeats | DPMA | Max safety net | General Patient Charge |
|---|---|---|---|---|
| Max amount: 400 mg | # of repeats: 7 | DPMA: $14,870.58 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | ||||
| Keytruda
(pembrolizumab 100 mg/4 mL injection, 4 mL vial)
|
||||
